Retrospective Analysis of Data Evaluating Safety and Efficacy of REBYOTA™ (fecal microbiota, live – jslm) in a Real-World Patient Population with Comorbidities and Risk Factors Published in Open Forum Infectious Diseases
The AAT program offered REBYOTA to adults not eligible for clinical trial participation or who needed additional treatment following study participation.
- The AAT program offered REBYOTA to adults not eligible for clinical trial participation or who needed additional treatment following study participation.
- The primary objective was to evaluate the safety and tolerability of REBYOTA through six months after treatment.
- The secondary objectives were to evaluate efficacy in preventing rCDI within eight weeks of treatment and sustained response for six months after treatment.
- We are committed to ongoing research to help as many patients as possible who are living with recurrent C. diff infection.”